Key Highlights

  • Shares trading down 2.23% to $1.10 in today's session.
  • Trading Volume reached 128.55 thousand shares, with a 52-week range of $0.91 to $46.50.
  • The company reported an EPS of negative $25.44, reflecting continued losses.
  • The stock remains well below its pandemic-era highs, with annual Revenue now under $1 million.

New Contract Expands Vector Smart's Reach, But Shares Still Slip

Co-Diagnostics, Inc. (NASDAQ:CODX), a Salt Lake City-based molecular diagnostics company known for its PCR-based testing platform, announced it secured an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart laboratory installation, marking the company's first complete installation of this kind for a Native American tribe. The agreement allows the tribe to perform PCR-based testing of mosquito pools locally rather than relying on outside facilities. Despite the announcement, shares were trading down, suggesting the contract alone was not enough to shift sentiment on the stock.

Revenue Pressure Continues to Weigh on Shares

The company's financial profile remains strained, with annual revenue now well under $1 million, a steep decline from its pandemic-era peak. The stock's 52-week range stretching from $0.91 to $46.50 reflects the scale of that decline. An EPS of negative $25.44 underscores ongoing losses as the company works to diversify its revenue base beyond its legacy COVID-19 testing business.

Point-of-Care Platform Still Pending Regulatory Review

Beyond Vector Smart, Co-Diagnostics continues to develop its Co-Dx PCR platform for at-home and point-of-care use, though this product remains subject to regulatory review and is not yet available for sale. The company is also preparing a separate regulatory submission for an upper respiratory test, a step that could broaden its testing portfolio if cleared.

Outlook: Diversification Efforts Continue Amid a Thin Trading Base

Co-Diagnostics' push into public health and tribal testing contracts reflects an effort to build a steadier, non-pandemic revenue stream, though the stock's reaction today suggests investors are still weighing this shift against the company's broader financial pressures. With thin trading volume, the stock may continue to see outsized price swings on relatively routine news.